--- a
+++ b/clusters/9knumclustersv2/clust_1347.txt
@@ -0,0 +1,54 @@
+Receipt of live, attenuated vaccine within  days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of investigational treatment
+Receipt of a live vaccine within  days prior to registration for protocol therapy
+Receipt of a live, attenuated vaccine within  weeks prior to randomization, during treatment, or within  months following the last dose of atezolizumab/placebo
+Receipt of live vaccine within  days of planned first dose of TVEC
+Receipt of a live virus vaccine within  days prior to Day  of Cycle 
+Receipt of a live vaccine within  days of start of study treatment
+Receipt of a live virus vaccine within  days prior to Day  of Cycle 
+Receipt of live attenuated vaccine within  days prior to the first dose of study drug. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to  days after the last dose of study treatment.
+Receipt of live attenuated vaccine within  days prior to the first dose of IP. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving IP and up to  days after the last dose of IP.
+Receipt of attenuated vaccine within  weeks prior to starting study treatment.
+Receipt of a live vaccine =<  days prior to registration
+Receipt of live attenuated vaccine within  days before the first dose of study treatment
+Receipt of live attenuated vaccination within  days prior to the first dose of IP; Note: Patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of IP
+Receipt of live attenuated vaccine within  calendar days prior to the first study treatment is NOT permitted
+Receipt of live attenuated vaccination within  days prior the first dose of durvalumab (NOTE: If a vaccine is part of the treatment regimen for the indication under study, the vaccine is permitted)
+Receipt of live attenuated vaccine within  days prior to study entry; enrolled patients should not receive live vaccine during the study and  days after the last dose of durvalumab
+Receipt of a live vaccine within  days of receipt of study therapy
+Receipt of a live virus vaccine =<  months prior to registration
+Receipt of live attenuated vaccination within  days prior to study entry or within  days of receiving durvalumab (e.g. live attenuated influenza vaccine [LAIV], measles/mumps/rubella vaccine [MMR], variola virus vaccine [VAR], zoster, yellow fever, etc.)
+Receipt of live, attenuated vaccine within  days prior to the first dose of investigational products (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and  days after the last dose of investigational products)
+Receipt of live, attenuated vaccine within  days prior to the first dose of durvalumab and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study and for  days after the last dose of both drugs)
+Receipt of a live/attenuated vaccine within  weeks prior to the screening visit.
+Receipt of a live vaccine within  days of study entry
+Receipt of live, attenuated vaccine within  days prior to the first dose of durvalumab (Note: enrolled patients should not receive live vaccine during the study and for  days after the last dose of durvalumab)
+Receipt of a live, attenuated vaccine within  days prior to the first dose of MEDI and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study or for  days after the last dose of both drugs)
+Receipt of live attenuated vaccine within  days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of IP.
+Receipt of live or live attenuated vaccine within  weeks prior to enrollment
+Receipt of live vaccine within  days prior to the first dose of trial treatment
+Receipt of any live vaccine within  weeks.
+Receipt of live attenuated vaccine within  days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of investigational treatment
+Receipt of live attenuated vaccine within  days prior to the first dose of study drugs; Note: Patients, if enrolled, should not receive live vaccine whilst receiving treatment with study drugs and up to  days after the last dose of study drugs
+Receipt of live, attenuated vaccine within  days prior to study entry or the first dose of MEDI.\r\n* Note: patients, if enrolled, should not receive live vaccine during the study and up to  days after the last dose of IP.
+Receipt of live, attenuated vaccine within  days prior to the first dose of durvalumab
+Receipt of live, attenuated vaccine within  days prior to the first dose of investigational product
+Receipt of live, attenuated vaccine within  days prior to the first dose of IP (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and for  days after the last dose of durvalumab).
+Receipt of a live vaccine within  days before the first dose of study treatment.
+Any non-oncology live or attenuated vaccine therapy used for prevention of infectious diseases within  days prior to the first dose of tremelimumab; if patients is enrolled, patient should not receive live vaccine during the study and  days after the last dose of tremelimumab
+Receipt of a live vaccine within  weeks prior to rituximab administration
+Receipt of a live attenuated vaccine within  weeks prior to study drug
+Receipt of live attenuated vaccine within  days prior to the first dose of IP
+Receipt of live, attenuated vaccine within  days prior to the first dose of MEDI
+Receipt of live, attenuated vaccine within  days prior to the first dose of Investigational Product;
+Receipt of live, attenuated vaccine within  days prior to the first dose of investigational products )
+Receipt of live, attenuated vaccine within  days prior to the first dose of MEDI
+Receipt of a live vaccine within  days of receipt of study therapy
+Receipt of a live (attenuated) vaccine within  month prior to Screening
+Receipt of a live virus vaccine within  days prior to Day  of Cycle 
+Receipt of a live vaccine within  days of receipt of study therapy
+No receipt of a live vaccine within  weeks prior to registration
+Receipt of live vaccine within  weeks prior to study drug administration
+Receipt of live attenuated vaccination within  days prior to study entry or within  days of receiving durvalumab; for example, the intramuscular influenza vaccine can be administered but the intranasal vaccine is a live attenuated virus that cannot be given
+Receipt of any live vaccine within  weeks prior to first dose of study treatment.
+Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.
+Receipt of live attenuated vaccination within  days prior to the first vaccine